Primary Sjögren's syndrome is one of the most common autoimmune diseases. To identify novel genetic susceptibility loci for primary Sjögren's syndrome, we performed a three-stage genome-wide association study (GWAS) in Han Chinese. At the discovery stage, 556,134 autosomal SNPs were analyzed in 542 cases and 1,050 controls. Promising associations were validated in two-stage replications with 1,303 cases and 2,727 controls. The combined analysis identified a new susceptibility locus for primary Sjögren's syndrome. Our analysis also confirmed previously reported primary Sjögren's syndrome associations in Europeans in several loci. Fine mapping of the region around the new locus confirmed the association and further extended the region of the new locus.
Online protocols Study design
We used a three-stage study design. The discovery GWAS stage included 556,134 autosomal SNPs in 542 cases and 1,050 controls of Han Chinese origin. The replication I stage contained 33 promising SNPs in 665 cases and 864 controls; the replication II stage included 17 (out of the 33) SNPs in 638 cases and 1,863 controls. We also performed fine mapping around the newly-identified susceptibility locus by genotyping tag SNPs and performing imputation. In fine mapping, we used 600 cases and 1,100 controls (all Han Chinese), of which 496 cases and 530 controls were case-control samples at the discovery GWAS stage and 104 cases and 570 controls were newly collected. A summary of samples in our study is in Supplementary Table 1 .
Collecting study samples and genotyping in GWAS
All the cases were recruited through cooperation of forty centers in China (the list of centers is included in authors' affiliations). All cases were diagnosed with primary Sjögren's syndrome by at least two rheumatologists according to the American-European Consensus Group (AECG) criteria for primary Sjögren's syndrome 1 and without any other autoimmune disease. All controls were recruited from the Peking Union Medical College Hospital according to the following rules: (i) no significant history of disease, (ii) no family history of rheumatologic diseases, (iii) normal biochemical and immunological profile, and (iv) negative serology of anti-Ro (SSA) and anti-La (SSB). Informed consent was given by each individual at recruitment. Approval for our study was obtained from the institutional review board of Peking Union Medical College Hospital. For all case and control individuals recruited in our study, anti-Ro (SSA)/anti-La (SSB) antibodies were detected by ELISA (EUROIMMUN AG, Germany), and genomic DNA was extracted from peripheral blood samples using the whole blood DNA extraction kit (solution type) (BioTeke, China). Genome-wide genotyping analysis was conducted using Affymetrix Axiom TM Genome-Wide CHB 1 Array Plate (Affymetrix) with 642,832 SNPs at CapitalBio Co. Ltd.
Genome-wide genotypes were called by the Axiom TM GT1 algorithm.
Quality control (QC) in GWAS

QC for individuals (including population stratification)
A systemic quality control (QC) was performed for individuals and SNPs. The step-wise QC for individuals at the discovery stage (597 cases and 1,090 controls) was to remove individuals with: principal components) was adapted to R 2.8.1 (http://www.r-project.org/) for plotting, and the first two eigenvectors were plotted. Population outlier is defined as individual with > 6 s.d. from the mean for any of the top 10 eigenvectors. Results confirmed that our samples were of East Asian ancestry and no population outlier was present. Population stratification was also assessed by only using the case-control data, and the Tracy-Widom test was employed to detect significant eigenvectors (P < 0.05). It turned out that the first eigenvector (eigenvector 1) was significant, which was used as one of the covariates in the subsequent statistical analysis. Summary of the QC-passed individuals is shown in Supplementary Table 1 .
QC for SNPs
After QC for individuals, QC for SNPs was performed to remove SNPs with: (i) per SNP call rate < 98% either in cases or controls, (ii) Hardy-Weinberg equilibrium (HWE) test P-value < 0.001 for controls, (iii) minor allele frequency (MAF) < 1% either in cases or controls, (iv) significantly different call rates between cases and controls (P < 1×10 -5 , PLINK command --test-missing) 9 , and (v) not mapped to autosomes. In total, there were 556,134 SNPs remaining after QC.
SNP selection for replication and genotyping in replication stages
SNP selection for replication I stage
For SNPs in the non-MHC regions with P < 5×10 -5 , we grouped SNPs based on their LD information and physical location. Any two SNPs with r 2 > 0.3 (LD was calculated within a distance of 1 Mb), together with the SNPs located between them, were put into the same group, so that each group represented an approximately independent region. For each region, the SNP with the lowest P-value was selected for replication (n = 23). For SNPs in MHC region with P < 5×10 -8 , we selected the representative SNPs obtained by conditional logistic regression analysis (n = 2).
Besides these SNPs, additional non-MHC SNPs that showed an association signal with primary Sjögren's syndrome (P < 5×10 -2 ) and that had been identified by GWAS (based on NHGRI GWAS Catalog, http://www.genome.gov/gwastudies/) 10 to be associated with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or primary biliary cirrhosis (PBC) (data by September 30 th 2012), were also selected for replication (n = 8). We removed the SNPs with problem cluster plots (analyzed by Affymetrix Genotyping Console). In total, 33 SNPs were selected for the replication I stage.
Genotyping in replication stages and platform validation
The genotyping at replication stages (I + II) was performed by the iPLEX MassARRAY platform (Sequenom). To validate the concordance between Affymetrix platform and Sequenom platform, we randomly selected 120 QC-passed individuals (60 cases and 60 controls) genotyped at the discovery stage, and re-genotyped the 33 SNPs selected for replication I using MassARRAY.
SNPs with per SNP concordance < 98 % were excluded from further analyses.
SNP selection for replication II stage
The SNPs which passed platform concordance validation and QC (see below for details) in replication I, as well as with the same association directions in discovery GWAS and replication I stage, were selected for replication II stage (18 out of 33 SNPs).
QC in replication studies
For quality control (QC) at replication stages I and II, we excluded SNPs with (i) call rate < 95% either in cases or controls, (ii) Hardy-Weinberg equilibrium (HWE) test P-value < 0.001 in controls, (iii) MAF < 1% either in cases or controls, and (iv) significantly different call rates between cases and controls (P < 1×10 -5 , PLINK command --test-missing). After QC on genotype data in replication II, 17 SNPs remained for a combined analysis.
Statistical analysis
The association test of SNPs with primary Sjögren's syndrome risk in the GWAS, replication stages and combined analysis was carried out by PLINK v1.07 11 using an additive model (minor allele count) in logistic regression. At the discovery stage, SNP-trait association P-values were calculated with gender, age and eigenvector 1 of PCA as covariates. The Manhattan plot of genome-wide -log 10 P was drawn by HaploView v4.1 12 , and the quantile-quantile (Q-Q) plot of genome-wide -log 10 P was generated by R 2.8.1 (http://www.r-project.org/). The genomic control inflation factor λ was calculated by R. Conditional logistic regression (PLINK command --condition) was employed to detect independent association signals in the MHC region and residual association in the three non-MHC loci by calculating SNP P-values conditioned upon the most significant SNP. Then all independent SNPs were put into one regression model with adjustment for gender, age and PCA-based correction to calculate ORs and P-values. The plots of genotype frequency variations between cases and controls of the genome-wide significant SNPs were also drawn by R. Association analyses at the replication stages were implemented with gender and age as covariates, and in combined analysis, besides gender and age, eigenvector 1 and indicator of stage were used as covariates (eigenvector 1 was set to zero for the data of replication I and II).
Moreover, meta-analysis was conducted by PLINK for the SNPs with genome-wide significance, where Cochran's Q test P-value and heterogeneity index I 2 were calculated to test stage heterogeneity. Epistasis (PLINK) and interaction test by partitioning chi-squares 13 were both performed to detect SNPs interacting with the three non-MHC genome-wide significant SNPs (P interaction < 5×10 -8 ). For pairwise interaction of the three SNPs, all P interaction exceeded 5×10 -2 after Bonferroni correction for the number of three SNP pairs. All association test P-values were two-sided and are reported without multiple testing corrections. Genome-wide significance was considered as a P-value < 5×10 -8 as generally used in GWAS.
Imputation and regional association plot
We utilized MACH 1.0 14 to impute non-genotyped SNPs using the CHB data (97 individuals) of the 1000 Genomes Integrated Phase 1 Release 15 as reference panel. Only the imputed SNPs with squared correlation between imputed and true genotypes (Rsq) > 0.5 were kept and imputation result (dosage data) was analyzed by mach2dat 14 . Regional results of association were plotted by LocusZoom (stand-alone version) 16 .
Fine mapping
We started from the newly-identified locus and its downstream gene to define the exact region for fine mapping. The initial region and its overlapping LD blocks represent a 220-kb region (74.00-74.22 Mb). To remedy the low coverage of the genome-wide SNP chip in the region, we further extended the 220-kb region to a 560-kb region (73.95-74.51 Mb), which includes all LD blocks containing SNPs that have an r 2 > 0.3 with any of the SNPs in the 220-kb region.
Haploview was utilized to select tag SNPs with MAF > 0.05, by using Paul de Bakker's Tagger algorithm with threshold r 2 > 0.9 on the basis of CHB data of the 1000 Genomes Integrated Phase 1 Release. SNPs with primer design problem were excluded. Genotyping was performed by the iPLEX MassArray platform (Sequenom). QC for SNPs is the same as that used in replication stages. The results of fine mapping confirmed the association of the new locus and further extended the region of the new locus.
Additional check for genotyping quality
For genome-wide significant SNPs identified in three-stage GWAS and fine mapping, we checked their cluster plots and intensity plots of each stage and investigated MAF across plates. All plots are very clear (Supplementary Fig. 7 ) and the mean of MAF across plates is very close to the MAF of overall plates, with very small standard deviation ( Supplementary Table 8 ).
